zika
viru
zikv
recent
emerg
mosquitoborn
member
famili
flavivirida
declar
word
health
organ
global
public
health
emerg
februari
like
flavivirus
viral
particl
constitut
inner
nucleocapsid
compos
capsid
c
protein
associ
viral
genom
rna
grna
surround
lipid
bilay
contain
structur
membran
envelop
e
protein
arrang
icosahedr
symmetri
surfac
viral
genom
consist
posit
singlestrand
rna
molecul
kb
similarli
cellular
mrna
contain
cap
structur
end
singl
open
read
frame
orf
flank
untransl
region
utr
orf
encod
larg
polyprotein
approxim
amino
acid
co
posttransl
process
viral
cellular
proteas
three
structur
protein
c
premembran
prm
e
seven
nonstructur
ns
protein
structur
protein
essenti
compon
virion
involv
viral
entri
fusion
assembl
ns
protein
requir
viral
rna
synthesi
virion
assembl
evas
host
antivir
respons
human
ill
caus
zikv
infect
first
recogn
nigeria
case
zikv
infect
across
africa
asia
report
year
histor
zikv
consid
modest
public
health
concern
caus
mild
febril
ill
similar
symptom
dengu
denv
chikungunya
chikv
virus
hamper
differenti
diagnosi
gener
zikv
case
asymptomat
remain
case
typic
exhibit
mild
fever
maculopapular
rash
joint
pain
period
sever
day
week
howev
recent
larg
outbreak
island
yap
french
polynesia
massiv
epidem
emerg
brazil
rapidli
spread
throughout
south
central
america
caribbean
recent
unit
state
chang
histor
perspect
zikv
infect
due
associ
syndrom
debilit
neuron
diseas
adult
sever
congenit
abnorm
us
stillbirth
hydrocephali
microcephali
collect
known
congenit
zikv
syndrom
czv
human
health
concern
pose
zikv
aggrav
due
nonvectorborn
transmiss
zikv
viru
spread
peopl
primarili
bite
infect
mosquito
genu
aed
howev
differ
flavivirus
zikv
also
transmit
mother
child
pregnanc
spread
sexual
contact
breastfeed
blood
transfus
nonhuman
primat
bite
due
recent
emerg
zikv
import
human
pathogen
current
approv
vaccin
antivir
avail
combat
zikv
infect
avail
diseas
prevent
measur
consist
protect
mosquito
bite
exclud
pregnant
femal
travel
zikvendem
area
practic
safe
sex
signific
zikv
human
health
togeth
lack
prophylact
therapeut
intervent
combat
zikv
infect
highlight
import
develop
safe
effect
countermeasur
control
prevent
zikv
diseas
human
sens
develop
zikv
revers
genet
system
constitut
essenti
tool
basic
research
develop
vaccin
antivir
strategi
likewis
flavivirus
construct
zikv
infecti
clone
hamper
due
toxic
flaviviru
sequenc
propag
bacteria
use
standard
high
copi
number
plasmid
attribut
leaki
express
toxic
viral
protein
cryptic
bacteri
promot
cbp
encod
viral
genom
recent
toxic
problem
overcom
use
nontradit
approach
base
vitro
ligat
cdna
fragment
lowcopi
plasmid
intron
insert
toxic
region
gibson
assembl
method
infecti
subgenom
amplicon
isa
silico
predict
mutat
silenc
cbp
present
viral
genom
use
circular
polymeras
extens
reaction
cper
system
valuabl
tool
studi
viral
pathogenesi
vector
transmiss
develop
attenu
form
zikv
implement
safe
vaccin
identif
therapeut
present
studi
report
differ
effici
zikv
revers
genet
approach
base
use
bacteri
artifici
chromosom
bac
overcom
toxic
problem
allow
gener
zikv
cdna
clone
singl
bacteri
plasmid
follow
similar
strategi
use
denv
fulllength
cdna
copi
viral
genom
zikv
rio
grand
nort
natal
rgn
assembl
bac
control
cytomegaloviru
cmv
immediateearli
promot
dnalaunch
system
coupl
express
viral
rna
nucleu
cmv
promot
second
amplif
step
cytoplasm
driven
viral
polymeras
recombin
viru
rescu
bac
clone
fulli
infecti
vitro
vivo
zikvrgn
infecti
clone
use
evalu
effect
singl
amino
acid
chang
alanin
valin
residu
protein
viral
rna
synthesi
pathogenesi
vivo
found
uniqu
singl
amino
acid
substitut
impair
viral
rna
synthesi
cell
cultur
result
viral
attenu
mice
remark
singl
dose
mutant
viru
suffici
induc
protect
challeng
parent
wildtyp
wt
zikv
result
demonstr
reliabl
potenti
bac
approach
studi
zikv
biolog
facilit
develop
vaccin
antivir
strategi
vero
kidney
epitheli
cell
line
african
green
monkey
human
adenocarcinom
alveolar
epitheli
cell
line
cell
purchas
american
type
cultur
collect
atcc
grown
maintain
growth
medium
consist
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
hyclon
thermofish
scientif
madrid
spain
mm
lglutamin
sigmaaldrich
madrid
spain
nonessenti
amino
acid
sigmaaldrich
uml
penicillin
sigmaaldrich
streptomycin
sigmaaldrich
recombin
zikvrgn
wt
rzikvrgn
mutant
virus
propag
vero
cell
viru
growth
medium
dmem
supplement
fb
mm
lglutamin
nonessenti
amino
acid
uml
penicillin
streptomycin
viru
stock
prepar
confluent
monolay
vero
cell
infect
multipl
infect
moi
plaqu
form
unit
pfu
per
cell
viru
growth
medium
incub
day
infect
tissu
cultur
supernat
collect
clarifi
centrifug
g
min
store
small
aliquot
bac
plasmid
kindli
provid
h
shizuya
california
institut
technolog
pasadena
ca
usa
use
assembl
zikvrgn
infecti
cdna
clone
plasmid
synthet
lowcopynumb
plasmid
one
copi
per
cell
base
escherichia
coli
e
coli
ffactor
minim
toxic
problem
bacteria
exogen
sequenc
e
coli
cell
invitrogen
thermofish
scientif
use
amplifi
bac
plasmid
electrocompet
cell
invitrogen
thermofish
scientif
transform
electropor
use
micropuls
unit
biorad
madrid
spain
accord
manufactur
instruct
bacbas
plasmid
isol
purifi
use
largeconstruct
kit
qiagen
hilden
germani
follow
manufactur
specif
assembl
zikv
infecti
cdna
clone
bac
plasmid
base
data
fulllength
sequenc
zikv
clinic
strain
rgn
deposit
genbank
access
number
strain
select
fulllength
sequenc
obtain
directli
virusinfect
brain
tissu
abort
fetu
microcephali
brazil
therefor
repres
good
candid
studi
zikv
pathogenesi
first
step
assembl
fulllength
cdna
clone
select
restrict
site
pmli
afei
bstbi
genom
posit
respect
uniqu
viral
genom
figur
four
overlap
dna
fragment
cover
entir
viral
genom
zikv
zikv
flank
appropri
restrict
site
gener
chemic
synthesi
bio
basic
inc
toronto
canada
figur
zikv
fragment
contain
cmv
promot
precis
fuse
first
nucleotid
viral
genom
flank
end
apali
asci
absent
viral
genom
site
end
multipleclon
site
contain
select
restrict
site
pmli
afei
bstbi
follow
mlui
absent
viral
genom
bamhi
fragment
zikv
flank
pmli
afei
zikv
flank
afei
bstbi
cover
genom
region
respect
zikv
fragment
contain
restrict
site
bstbi
last
nucleotid
viral
genom
hepat
delta
viru
hdv
ribozym
bovin
growth
hormon
bgh
termin
polyadenyl
sequenc
mlui
restrict
site
infecti
clone
assembl
sequenti
clone
four
overlap
dna
fragment
briefli
fragment
zikv
digest
apali
bamhi
clone
without
afei
restrict
site
digest
enzym
gener
intermedi
plasmid
plasmid
use
backbon
sequenti
clone
remain
overlap
dna
fragment
zikv
zikv
multiclon
site
intermedi
plasmid
contain
restrict
site
select
pmli
afei
bstbi
mlui
gener
fulllength
cdna
clone
pbaczikvrgn
figur
genet
integr
cdna
clone
verifi
throughout
assembl
process
extens
restrict
analysi
sequenc
case
bacteri
strain
invitrogen
thermofish
scientif
use
e
coli
host
clone
step
propag
bac
cdna
clone
recov
infecti
viru
vero
cell
plate
grown
confluenc
growth
medium
without
antibiot
transfect
bac
cdna
clone
use
lipofectamin
invitrogen
thermofish
scientif
follow
manufactur
specif
h
incub
transfect
medium
replac
fresh
growth
medium
cell
incub
aliquot
cultur
supernat
collect
h
interv
viru
titer
determin
plaqu
assay
vero
cell
five
seven
day
transfect
cytopath
effect
cpe
clear
cell
cultur
supernat
harvest
recov
viru
clone
three
round
plaqu
purif
determin
complet
genom
sequenc
rescu
virus
virion
supernat
infect
vero
cell
moi
pfucel
purifi
wv
sucros
cushion
viral
rna
isol
purifi
viru
qiaamp
viral
rna
minikit
qiagen
follow
manufactur
instruct
deepsequenc
univers
rochest
genom
research
center
use
illumina
miseq
illumina
san
diego
ca
usa
briefli
total
viral
rna
fragment
control
sonic
dna
librari
gener
use
nebnext
mrna
librari
prep
master
mix
set
illumina
new
england
biolab
ipswich
usa
accord
manufactur
instruct
analyz
librari
size
qualiti
bioanalyz
agil
technolog
inc
santa
clara
ca
usa
deepsequenc
perform
use
miseq
illumina
raw
sequenc
read
analyz
use
swarm
custom
softwar
genom
termin
sequenc
determin
rapid
amplif
cdna
end
race
use
race
second
gener
kit
roch
basilea
switzerland
polyatail
ad
cdna
prior
race
reaction
use
polya
polymeras
new
england
biolab
follow
manufactur
instruct
analyz
genet
stabil
recombin
zikv
harbor
point
mutat
code
region
protein
total
rna
purifi
vero
cell
infect
virus
passag
passag
use
rneasi
minikit
qiagen
accord
manufactur
specif
purifi
rna
ng
revers
transcrib
rt
random
hexam
primer
use
highcapac
cdna
transcript
kit
life
technolog
thermofish
scientif
cdna
amplifi
pcr
forward
primer
span
nucleotid
viral
genom
revers
primer
complementari
nucleotid
viral
genom
final
amplicon
gener
cover
region
encod
protein
genom
region
sequenc
sanger
sequenc
macrogen
europ
amsterdam
netherland
use
specif
oligonucleotid
vero
cell
seed
plate
confluenc
infect
serial
dilut
viru
viru
growth
medium
without
fb
h
viral
absorpt
viral
inoculum
remov
cell
overlaid
ml
viru
growth
medium
contain
deaedextran
sigmaaldrich
agar
nobl
difco
thermofish
scientif
day
incub
cell
fix
formaldehyd
h
room
temperatur
overlaid
remov
viral
plaqu
visual
stain
crystal
violet
methanol
immunostain
panflaviviru
e
protein
monoclon
antibodi
mab
bei
resourc
use
vectastain
abc
kit
vector
laboratori
inc
burlingam
ca
usa
visibl
plaqu
count
viru
titer
calcul
pfuml
vero
cell
seed
plate
confluenc
infect
indic
virus
dilut
viru
growth
medium
without
fb
specifi
moi
h
absorpt
viru
inoculum
remov
cell
monolay
wash
twice
pb
ml
fresh
viru
growth
medium
ad
well
cell
incub
select
time
point
aliquot
tissu
cultur
supernat
collect
viru
titer
determin
plaqu
assay
vero
cell
describ
viral
rna
synthesi
evalu
quantit
rtpcr
rtqpcr
total
intracellular
rna
uninfect
infect
vero
cell
purifi
use
rneasi
minikit
qiagen
total
cdna
synthet
ng
purifi
rna
use
random
hexam
primer
highcapac
cdna
transcript
kit
life
technolog
thermofish
scientif
follow
manufactur
specif
use
cdna
level
viral
rna
quantifi
qpcr
use
custom
taqman
assay
specif
zikvrgn
rna
taqman
assay
constitut
forward
primer
span
nucleotid
viral
genom
revers
primer
complementari
nucleotid
viral
genom
probe
cover
nucleotid
viral
genom
normal
differ
rna
sampl
express
histon
refer
housekeep
gene
analyz
use
specif
taqman
gene
express
assay
life
technolog
thermofish
scientif
data
acquir
realtim
pcr
system
life
technolog
thermofish
scientif
analyz
abi
prism
softwar
rel
quantif
perform
use
cycl
threshold
method
experi
data
analysi
miqe
minimum
inform
public
quantit
realtim
pcr
experi
compliant
express
zikv
e
protein
analyz
indirect
immunofluoresc
assay
ifa
vero
cell
grown
coverslip
plate
confluenc
infect
rescu
rzikv
indic
moi
select
time
point
postinfect
cell
fix
paraformaldehyd
mm
hepe
ph
min
room
temperatur
permeabil
triton
pb
min
cell
treat
h
room
temperatur
block
solut
fb
pb
incub
panflaviviru
e
protein
mab
bei
resourc
block
solut
h
room
temperatur
three
wash
pb
cell
incub
room
temperatur
h
donkey
antimous
antibodi
conjug
alexa
fluor
invitrogen
thermofish
scientif
dilut
block
solut
extens
wash
pb
incub
min
dapi
sigmaaldrich
dilut
pb
nuclear
stain
final
coverslip
mount
prolong
gold
antifad
reagent
invitrogen
thermofish
scientif
analyz
leica
confoc
microscop
immunofluoresc
acquir
imag
process
analyz
imagej
softwar
evalu
virusspecif
antibodi
level
present
sera
vaccin
mice
enzymelink
immunosorb
assay
elisa
perform
previous
describ
briefli
plate
coat
cell
lysat
mock
zikvinfect
vero
cell
incub
overnight
coat
well
wash
pb
block
bsa
pb
incub
twofold
dilut
start
dilut
mice
sera
h
plate
wash
water
incub
hrpconjug
goat
antimous
igg
southern
biotech
birmingham
al
usa
h
reaction
develop
tetramethylbenzidin
tmb
substrat
biolegend
san
diego
ca
usa
min
room
temperatur
quench
n
read
nm
vmax
kinet
micropl
reader
molecular
devic
san
jose
ca
usa
vivo
studi
perform
typei
interferon
ifn
receptor
defici
ifnr
mice
jackson
laboratori
bar
harbor
usa
maintain
anim
care
facil
univers
rochest
specif
pathogenfre
condit
anim
model
subcutan
sc
intraperiton
ip
infect
zikv
induc
neurolog
diseas
anim
succumb
viral
infect
high
viral
load
blood
brain
spin
cord
test
consist
manifest
zikv
infect
human
although
defici
innat
ifn
respons
mice
retain
adapt
immun
success
use
suitabl
model
test
antivir
vaccin
evalu
viru
pathogen
femal
mice
n
first
anesthet
ip
mixtur
ketamin
per
gram
bodi
weight
xylazin
per
gram
bodi
weight
mockinfect
pb
infect
sc
footpad
indic
dose
rzikvrgn
dilut
pb
final
volum
viral
infect
anim
monitor
daili
morbid
bodi
weight
loss
diseas
sign
includ
hunch
ruffl
hind
limb
paralysi
mortal
surviv
day
mice
show
bodi
weight
loss
sever
paralysi
consid
reach
experiment
endpoint
human
euthan
correl
develop
clinic
symptom
death
viru
replic
mice
n
infect
describ
viral
titer
serum
determin
day
n
n
plaqu
assay
immunostain
use
panflaviviru
e
protein
mab
indic
evalu
protect
efficaci
femal
mice
n
first
anesthet
ip
indic
mockimmun
pb
immun
sc
footpad
pfu
dilut
pb
final
volum
day
postimmun
mous
sera
collect
submandibular
bleed
presenc
total
antibodi
zikvrgn
evalu
elisa
twentyfour
hour
bleed
mice
challeng
sc
footpad
pfu
rzikvrgn
morbid
mortal
monitor
day
previous
describ
determin
viral
replic
challeng
mice
n
bleed
day
n
n
postchalleng
zikv
viremia
determin
plaqu
assay
immunostain
use
panflaviviru
e
protein
mab
previous
describ
quantit
analys
twotail
unpair
student
test
use
analyz
differ
mean
valu
group
result
express
mean
standard
deviat
mean
p
valu
consid
signific
mice
experi
meier
logrank
test
use
compar
surviv
data
reed
muench
method
determin
mous
lethal
dose
graphpad
prism
softwar
use
statist
analysi
anim
protocol
approv
univers
rochest
committe
anim
resourc
protocol
number
approv
date
compli
recommend
guid
care
use
laboratori
anim
nation
research
council
overcom
toxic
problem
associ
sever
flaviviru
sequenc
propag
bacteria
use
bac
plasmid
singlecopi
plasmid
deriv
e
coli
ffactor
assembl
zikv
infecti
cdna
clone
base
genom
sequenc
rgn
strain
zikv
genbank
access
number
figur
zikvrgn
strain
select
laboratori
passag
histori
fulllength
genom
sequenc
obtain
zikvinfect
fetu
microcephali
constitut
good
candid
studi
zikv
pathogenesi
appropri
select
uniqu
restrict
site
zikvrgn
genom
figur
four
overlap
dna
fragment
zikv
zikv
span
fulllength
viral
genom
flank
select
restrict
site
chemic
synthes
sequenti
clone
gener
infecti
cdna
clone
pbaczikvrgn
figur
fragment
zikv
contain
cmv
immediateearli
promot
allow
express
viral
rna
nucleu
cellular
rna
polymeras
ii
fragment
zikv
flank
end
hdv
ribozym
follow
bgh
termin
polyadenyl
sequenc
produc
synthet
rna
bear
authent
end
viral
genom
dnalunch
system
ensur
cap
viral
rna
allow
recoveri
infecti
viru
transfect
cdna
clone
without
need
vitro
transcript
step
assembl
fulllength
sequenc
zikvrgn
bac
clone
determin
chang
detect
report
zikvrgn
strain
genbank
access
number
final
confirm
stabil
synthet
infecti
cdna
clone
bacteria
bac
clone
passag
e
coli
cell
two
hundr
gener
genet
integr
passag
infecti
clone
analyz
restrict
endonucleas
analysi
sequenc
differ
detect
demonstr
zikvrgn
bac
clone
fulli
stabl
bacteria
bac
approach
reliabl
simpl
method
gener
zikv
infecti
cdna
clone
recov
infecti
viru
figur
vero
cell
transient
transfect
bac
cdna
clone
use
lipofectamin
viru
product
analyz
seven
day
contrast
mocktransfect
cell
increas
amount
infecti
viru
detect
tissu
cultur
supernat
cell
transfect
infecti
clone
peak
titer
around
pfuml
day
five
figur
confirm
ident
rescu
viru
vero
cell
infect
moi
pfucel
rescu
viru
monitor
cpe
induct
viral
e
protein
express
ifa
use
panflaviviru
e
protein
mab
figur
rescu
viru
induc
clear
cpe
character
presenc
round
birefring
cell
high
level
e
protein
express
detect
perinuclear
region
infect
cell
result
demonstr
zikvrgn
infecti
bac
cdna
clone
produc
high
titer
rzikvrgn
directli
transfect
suscept
vero
cell
ident
rescu
viru
confirm
clone
three
round
plaqu
purif
phenotyp
genotyp
properti
determin
analysi
growth
kinet
reveal
rzikvrgn
replic
effici
vero
cell
reach
peak
titer
approxim
pfuml
hpi
respect
figur
addit
rescu
viru
gener
homogen
plaqu
mm
size
four
day
infect
vero
cell
figur
final
genet
ident
viru
analyz
deepsequenc
two
independ
clone
fullgenom
sequenc
viral
clone
reveal
clone
present
sequenc
cdna
clone
overal
result
demonstr
feasibl
gener
infecti
rzikv
use
bacbas
approach
determin
whether
rescu
rzikvrgn
pathogen
vivo
figur
group
five
femal
mice
ifnr
inocul
sc
footpad
pb
neg
control
differ
dose
rzikvrgn
pfu
per
anim
morbid
bodi
weight
loss
diseas
sign
surviv
monitor
daili
day
figur
expect
weight
loss
surviv
correl
inocul
dose
mice
infect
pfu
show
diseas
symptom
slight
reduct
bodi
weight
detect
day
surviv
case
mice
infect
pfu
present
symptom
diseas
hunch
reduc
mobil
weight
loss
day
seven
nine
maximum
day
nine
recov
initi
bodi
weight
surviv
contrast
anim
infect
pfu
show
hind
limb
paralysi
rapidli
lost
weight
succumb
viral
infect
day
seven
eight
postinfect
figur
use
reed
muench
method
determin
rzikvrgn
approxim
pfu
analyz
whether
virul
observ
correl
viral
replic
viral
titer
mous
sera
analyz
day
two
four
postinfect
figur
expect
viremia
infect
anim
dose
depend
reach
highest
titer
day
two
inocul
day
four
postinocul
signific
reduct
viral
titer
observ
case
anim
infect
pfu
viremia
detect
detect
one
three
infect
mice
respect
figur
overal
result
indic
rzikvrgn
recov
infecti
clone
virul
mice
high
pfu
dose
assembl
pbaczikvrgn
infecti
clone
detect
presenc
point
mutat
protein
introduc
chemic
synthesi
fragment
zikv
mutat
consist
cytosinetothymidin
substitut
genom
posit
result
alaninetovalin
chang
residu
protein
mutat
consist
conserv
amino
acid
chang
decid
explor
possibl
use
mutat
genet
marker
end
infecti
clone
gener
replac
zikv
wt
fragment
contain
mutat
infecti
clone
fulli
stabl
bacteria
addit
mutat
observ
sequenc
fulllength
clone
vero
cell
transfect
mutant
infecti
clone
recoveri
effici
mutant
viru
compar
parent
rzikvrgn
viru
figur
although
infecti
viru
recov
case
viru
product
one
logarithm
lower
case
mutant
reach
maximum
titer
pfuml
seven
day
posttransfect
figur
plaqu
phenotyp
analyz
found
plaqu
size
mutant
smaller
reduct
parent
rzikvrgn
figur
indic
mutat
despit
conserv
substitut
caus
reduct
plaqu
size
viru
product
addit
silico
analysi
perform
evalu
frequenc
amino
acid
residu
protein
zikv
strain
sequenc
deposit
databas
http
wwwviprbrcorgbrchomespg
decoratorflavi
analysi
indic
amino
acid
highli
conserv
sinc
analyz
zikv
sequenc
contain
alanin
residu
posit
confirm
effect
mutat
viru
product
growth
kinet
high
pfucel
low
pfucel
moi
mutant
viru
compar
parent
viru
figur
reduct
one
logarithm
unit
viru
product
detect
vero
cell
infect
mutant
viru
high
low
moi
figur
taken
consider
flaviviru
protein
involv
regul
rna
replic
viru
assembl
analyz
whether
reduct
plaqu
size
viru
product
mutant
viru
associ
reduc
viral
rna
synthesi
end
product
viral
rna
vero
cell
infect
either
parent
mutant
virus
moi
pfucel
analyz
hpi
rtqpcr
use
custom
taqman
assay
specif
zikvrgn
genom
figur
time
reduct
level
viral
rna
observ
cell
infect
mutant
viru
figur
confirm
mutat
least
impair
viral
rna
synthesi
agreement
data
reduct
express
level
zikv
e
protein
observ
ifa
vero
cell
infect
mutant
viru
comparison
cell
infect
parent
viru
figur
final
discard
presenc
undesir
mutat
fulllength
sequenc
mutant
viru
determin
deepsequenc
mutat
detect
collect
result
indic
mutat
alon
affect
zikv
growth
vero
cell
least
impair
viral
rna
synthesi
investig
whether
reduc
rna
synthesi
vero
cell
could
result
viral
attenu
vivo
abil
mutant
viru
induc
pathogenesi
analyz
mice
compar
parent
rzikvrgn
figur
end
group
five
femal
mice
inocul
sc
footpad
pfu
either
rzikvrgn
pb
neg
control
bodi
weight
loss
surviv
monitor
daili
day
contrast
mice
infect
rzikvrgn
quickli
lost
weight
die
day
eight
infect
mice
infect
mutant
present
clinic
sign
infect
weight
loss
surviv
viral
infect
figur
analyz
correl
attenu
mutant
viru
viral
replic
presenc
viru
mice
sera
analyz
day
two
four
postinfect
agreement
pathogen
data
mice
infect
mutant
viru
present
lower
viremia
mice
infect
parent
viru
figur
mutant
viru
detect
day
two
infect
lower
titer
approxim
logarithm
lower
parent
viru
intern
control
experi
plaqu
phenotyp
virus
recov
blood
infect
mice
analyz
expect
rzikvrgn
form
big
plaqu
mutant
form
small
plaqu
figur
result
indic
highli
attenu
mice
compar
rzikvrgn
attenu
may
due
lower
replic
mutant
viru
elucid
attenu
vivo
abil
induc
protect
challeng
parent
rzikvrgn
analyz
figur
end
group
five
femal
mice
vaccin
sc
footpad
pfu
mockvaccin
pb
twenti
day
vaccin
blood
sampl
collect
evalu
humor
respons
one
day
later
mice
challeng
lethal
dose
pfu
rzikvrgn
bodi
weight
loss
surviv
analyz
daili
day
expect
mice
vaccin
pb
lost
weight
rapidli
show
clear
symptom
diseas
succumb
challeng
rzikvrgn
contrast
mice
vaccin
lose
weight
surviv
challeng
rzikvrgn
figur
indic
singl
immun
dose
enough
induc
full
protect
zikvrgn
agreement
data
strong
humor
respons
zikvrgn
observ
mice
vaccin
figur
viremia
detect
sera
sampl
vaccin
mice
day
two
four
challeng
figur
confirm
attenu
vivo
induc
protect
zikvrgn
mice
genet
stabil
mutant
viru
analyz
vero
cell
order
test
possibl
use
mutant
viru
base
develop
liveattenu
zikv
vaccin
figur
end
mutant
parent
rzikvrgn
virus
passag
five
time
vero
cell
viru
plaqu
phenotyp
growth
kinet
sequenc
analyz
passag
analysi
plaqu
phenotyp
show
parent
viru
present
expect
plaqu
size
throughout
passag
contrast
mutant
viru
revers
parent
plaqu
phenotyp
observ
revers
start
big
plaqu
clearli
increas
big
plaqu
complet
figur
analyz
whether
plaqu
size
revers
mutant
correl
increas
viru
replic
level
parent
viru
end
growth
kinet
moi
pfucel
mutant
viru
compar
parent
viru
growth
curv
analysi
show
contrast
mutant
viru
viru
replic
level
parent
viru
figur
suggest
mutant
viru
revert
wt
sequenc
propag
vero
cell
confirm
observ
code
region
mutant
virus
amplifi
rtpcr
sequenc
sequenc
analysi
confirm
revers
mutat
wt
sequenc
although
instabl
revers
mutant
viru
wt
sequenc
propag
vero
cell
limit
use
mutant
vaccin
develop
data
support
import
residu
viru
replic
moreov
data
also
suggest
zikv
protein
repres
good
target
develop
antivir
zikv
infect
signific
zikv
public
health
due
associ
syndrom
fetal
abnorm
togeth
lack
approv
antivir
agent
vaccin
trigger
global
effort
studi
flaviviru
order
develop
effect
strategi
prevent
control
zikv
infect
human
respect
develop
implement
revers
genet
approach
zikv
provid
investig
novel
power
experiment
tool
studi
biolog
pathogenesi
zikv
well
develop
attenu
form
zikv
implement
liveattenu
vaccin
howev
describ
flavivirus
gener
zikv
infecti
clone
use
tradit
approach
difficult
due
toxic
instabl
viral
sequenc
propag
clone
cdna
bacteria
past
two
year
sever
approach
overcom
toxic
problem
appli
success
gener
zikv
infecti
clone
includ
use
lowcopi
plasmid
insert
intron
disrupt
toxic
sequenc
mutat
silenc
cbp
present
viral
genom
vitro
ligat
cdna
fragment
isa
method
cper
approach
although
use
approach
labori
time
consum
present
sever
disadvantag
instanc
need
vitro
ligat
transcript
step
complic
assembl
reduc
recoveri
effici
moreov
low
recoveri
effici
increas
presenc
undesir
mutat
could
result
vitro
andor
vivo
attenu
limit
use
infecti
clone
certain
studi
other
mutat
silenc
cbp
high
number
silent
mutat
introduc
could
affect
viral
fit
final
use
lowcopi
plasmid
shown
effect
sever
zikv
strain
other
probabl
due
differ
degre
toxic
rna
sequenc
differ
strain
describ
power
approach
gener
infecti
cdna
clone
zikvrgn
strain
singl
plasmid
base
use
combin
synthet
biolog
bac
fulllength
cdna
copi
zikvrgn
strain
gener
four
synthet
dna
fragment
clone
bac
plasmid
control
cmv
promot
allow
express
viral
rna
nucleu
flank
end
hdv
ribozym
bgh
polyadenyl
termin
sequenc
produc
synthet
rna
bear
authent
end
viral
genom
bac
cdna
clone
fulli
stabl
propag
bacteria
function
infecti
viru
rescu
direct
transfect
suscept
vero
cell
pathogen
mice
zikvrgn
infecti
clone
gener
use
cper
approach
recent
report
howev
contrast
result
rescu
viru
asymptomat
nonleth
femal
mice
infect
dose
cell
cultur
infect
dose
via
sc
rout
whether
differ
pathogen
among
rzikvrgn
relat
experiment
approach
cper
versu
bac
age
mice
versu
moi
use
infect
mice
versu
pfu
remain
evalu
although
zikv
revers
genet
system
report
discuss
bac
approach
constitut
use
altern
present
import
advantag
bac
plasmid
present
strictli
control
replic
lead
one
plasmid
per
cell
therefor
minim
toxic
associ
sever
flaviviru
sequenc
amplifi
bacteria
allow
easi
direct
manipul
viral
genom
molecular
studi
ii
similarli
approach
use
poliidriven
promot
bac
approach
result
intracellular
express
viral
rna
allow
cap
viral
rna
recoveri
infecti
viru
without
need
vitro
transcript
step
although
splice
event
could
occur
nuclear
express
viral
genom
mainli
due
presenc
donor
acceptor
put
sequenc
viral
genom
effici
phenomenon
low
affect
recoveri
infecti
virus
iii
like
system
base
transfect
dna
construct
bac
cdna
clone
present
higher
effici
transfect
rna
transcript
mammalian
cell
allow
higher
effici
viru
recoveri
reduc
passag
cell
cultur
get
viral
stock
therefor
possibl
introduc
undesir
mutat
cell
cultur
adapt
iv
manipul
bac
cdna
clone
rel
easi
similar
convent
plasmid
slight
modif
due
presenc
one
plasmid
copi
per
cell
addit
standard
protocol
bac
cdna
clone
could
also
effici
modifi
e
coli
homolog
recombin
use
twostep
approach
combin
red
recombin
system
counterselect
home
endonucleas
iscei
v
bac
approach
success
use
engin
infecti
clone
flavivirus
includ
denv
sever
coronavirus
contain
largest
viral
rna
genom
known
similar
toxic
problem
describ
flavivirus
data
highlight
potenti
bac
approach
rapid
reliabl
construct
stabl
infecti
clone
emerg
flaviviru
similar
rna
virus
unstabl
viral
genom
amplifi
cdna
bacteria
zikv
revers
genet
system
describ
articl
use
studi
effect
singl
amino
acid
substitut
viral
protein
viru
growth
cultur
cell
pathogenesi
vivo
result
suggest
singl
amino
acid
chang
impair
viral
rna
synthesi
viru
product
cell
cultur
highli
attenu
viru
mice
howev
discard
mutat
protein
could
affect
step
replic
cycl
viru
flaviviru
protein
hydrophob
protein
associ
endoplasm
reticulum
contain
eight
transmembran
domain
multifunct
protein
involv
viral
rna
synthesi
viru
assembl
membran
rearrang
immunomodul
innat
immun
respons
homolog
denv
topolog
zikv
mutat
map
last
transmembran
domain
specif
function
report
therefor
data
constitut
first
evid
role
domain
viral
rna
synthesi
hand
import
note
mutat
promot
reduct
viral
rna
synthesi
reduct
viru
product
reduc
viru
product
could
consequ
rna
synthesi
impair
howev
sinc
reduct
viru
product
higher
observ
rna
synthesi
flaviviru
protein
also
involv
viru
assembl
discard
addit
effect
mutat
zikv
assembl
addit
found
mutant
viru
attenu
mice
attenu
could
explain
consequ
lower
rna
synthesi
mutant
viru
howev
addit
effect
mutat
put
immunomodulatori
role
protein
lead
virul
attenu
discard
futur
studi
requir
determin
whether
mutat
affect
viral
rna
synthesi
also
viru
assembl
immunomodul
host
defens
importantli
shown
immun
singl
dose
pfu
mutant
induc
protect
lethal
challeng
parent
rzikvrgn
suggest
potenti
implement
mutant
base
liveattenu
vaccin
unfortun
mutant
instabl
revert
wt
sequenc
propag
vero
cell
limit
use
mutat
alon
vaccin
develop
howev
instabl
high
conserv
amino
acid
protein
among
zikv
strain
highlight
import
residu
viru
replic
therefor
potenti
use
protein
good
target
antivir
develop
zikv
infect
summari
develop
power
zikv
revers
genet
system
base
use
bac
allow
us
identifi
singl
point
mutat
protein
attenu
viru
vitro
vivo
infecti
clone
system
provid
valuabl
tool
research
commun
explor
zikv
molecular
biolog
viral
determin
zikv
pathogenesi
virushost
interact
vaccin
antivir
develop
